Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Eun-Jung Rhee (Rhee EJ)
Endocrinol Metab. 2019;34(3):226-233.   Published online 2019 Sep 26     DOI: https://doi.org/10.3803/EnM.2019.34.3.226
Citations to this article as recorded by Crossref logo
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Ying-Xin Xian, Jian-Ping Weng, Fen Xu
Chinese Medical Journal.2021; 134(1): 8.     CrossRef
Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study
Matthias Claus, Christoph Antoni, Bernd Hofmann
BMC Gastroenterology.2021;[Epub]     CrossRef
Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model
P. Comeglio, E. Sarchielli, S. Filippi, I. Cellai, G. Guarnieri, A. Morelli, G. Rastrelli, E. Maseroli, S. Cipriani, T. Mello, A. Galli, B. J. Bruno, K. Kim, K. Vangara, K. Papangkorn, N. Chidambaram, M. V. Patel, M. Maggi, L. Vignozzi
Journal of Endocrinological Investigation.2021; 44(10): 2175.     CrossRef
Body Fat Distribution, Glucose Metabolism, and Diabetes Status Among Older Adults: The Multiethnic Cohort Adiposity Phenotype Study
Gertraud Maskarinec, Phyllis Raquinio, Bruce S. Kristal, Adrian A. Franke, Steven D. Buchthal, Thomas M. Ernst, Kristine R. Monroe, John A. Shepherd, Yurii B. Shvetsov, Loïc Le Marchand, Unhee Lim
Journal of Epidemiology.2021;[Epub]     CrossRef
Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis
Chien-Yu Lin, Pratik Adhikary, Kun Cheng
Advanced Drug Delivery Reviews.2021; 174: 127.     CrossRef
Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD)
Hiroshi Bando
Asploro Journal of Biomedical and Clinical Case Reports.2021; 4(2): 99.     CrossRef
Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems
Ye-Na Kweon, Hae-Jin Ko, A-Sol Kim, Hye-In Choi, Ji-Eun Song, Ji-Yeon Park, Sung-Min Kim, Hee-Eun Hong, Kyung-Jin Min
Healthcare.2021; 9(7): 899.     CrossRef
Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice
Yongxiang Yu, Dongru Chen, Yuhua Zhao, Jianjun Zhu, Xiaohui Dong
International Journal of Immunopathology and Pharmacology.2021; 35: 205873842110368.     CrossRef
Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
Jaskamal Padda, Khizer Khalid, Anwar Khedr, Fahriba Tasnim, Ola A Al-Ewaidat, Ayden Charlene Cooper, Gutteridge Jean-Charles
Cureus.2021;[Epub]     CrossRef
Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes
Sang Youn You, Kyungdo Han, Seung-Hawn Lee, Mee Kyoung Kim
Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai, Jian Gao Fan
Journal of Digestive Diseases.2021; 22(9): 536.     CrossRef
Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function
Teslime Ayaz, Hatice Beyazal Polat, Bilgesah Kilictas
International Journal of Diabetes in Developing Countries.2021;[Epub]     CrossRef
Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice
Tehila Daniel, Michaella Ben-Shachar, Elyashiv Drori, Sharleen Hamad, Anna Permyakova, Elad Ben-Cnaan, Joseph Tam, Zohar Kerem, Tovit Rosenzweig
The Journal of Nutritional Biochemistry.2021; 98: 108867.     CrossRef
The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease
Sylwia Ziolkowska, Agata Binienda, Maciej Jabłkowski, Janusz Szemraj, Piotr Czarny
International Journal of Molecular Sciences.2021; 22(20): 11128.     CrossRef
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Judith Aron-Wisnewsky, Chloé Vigliotti, Julia Witjes, Phuong Le, Adriaan G. Holleboom, Joanne Verheij, Max Nieuwdorp, Karine Clément
Nature Reviews Gastroenterology & Hepatology.2020; 17(5): 279.     CrossRef
Non-alcoholic fatty liver disease and primary care physicians
Ludovico Abenavoli, Anna C. Procopio, Milica Medić-Stojanoska, Francesco Luzza
Minerva Gastroenterologica e Dietologica.2020;[Epub]     CrossRef
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Hideki Fujii, Norifumi Kawada
International Journal of Molecular Sciences.2020; 21(11): 3863.     CrossRef
Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway
Yuanyuan Liu, Mengjie Wang, Wei Xu, Hongman Zhang, Weihe Qian, Xiang Li, Xingbo Cheng
Life Sciences.2020; 241: 117086.     CrossRef
Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease
Inha Jung, Hyemi Kwon, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
Atherosclerosis.2020; 308: 1.     CrossRef
The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
Xueyang Zhang, Ran Bai, Yong Jia, Junwei Zong, Yongbo Wang, Yanan Dong
International Journal of Diabetes in Developing Countries.2020; 40(4): 491.     CrossRef
Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients
Bin Huang, Shengju Yang, Shandong Ye
Journal of Diabetes Research.2020; 2020: 1.     CrossRef
The Absence of NLRP3-inflammasome Modulates Hepatic Fibrosis Progression, Lipid Metabolism, and Inflammation in KO NLRP3 Mice during Aging
Paloma Gallego, Beatriz Castejón-Vega, José A. del Campo, Mario D. Cordero
Cells.2020; 9(10): 2148.     CrossRef
Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil
Cassyano J. Correr, Wendel Coura-Vital, Josélia C. Q. P. Frade, Renata C. R. M. Nascimento, Lúbia G. Nascimento, Eliete B. Pinheiro, Wesley M. Ferreira, Janice S. Reis, Karla F. S. Melo, Roberto Pontarolo, Mônica S. A. Lenzi, José V. Almeida, Hermelinda C
Diabetology & Metabolic Syndrome.2020;[Epub]     CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef

Elevated TPOAb is a Strong Predictor of Autoimmune Development in Patients of Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Case–Control Study

Chenyi Wang, Qianglong Niu, Haihong Lv, Qian Li, Yuping Ma, Jiaojiao Tan, Chunhua Liu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4369.     CrossRef
Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice
Ayala Wollman, Tehila Daniel, Tovit Rosenzweig
Nutrients.2019; 11(12): 3044.     CrossRef